Circulating Tumor DNA
NCT06923527
This study is recruiting at 6 US sites in 6 states, according to its ClinicalTrials.gov record last updated .
Summary
This is a single-arm, phase II study examining elacestrant in the adjuvant treatment of patients with ER+ breast cancer who test positive for circulating tumor DNA (ctDNA) during the screening period of the trial. Our trial will proceed in three separate phases: screening, treatment, and follow-up.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- ER+ Breast Cancer
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 2
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Yale University
- Last updated on ClinicalTrials.gov
- September 21, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Connecticut · 1
- Yale University · New Haven, CT
District of Columbia · 1
- Lombardi Comprehensive Cancer Center at Georgetown University Medical Center · Washington D.C., DC
Maryland · 1
- Sidney Kimmel Comprehensive Cancer Center at John Hopkins · Baltimore, MD
Massachusetts · 1
- Dana-Farber Cancer Institute · Boston, MA
New York · 1
- Montefiore Einstein Comprehensive Cancer Center · The Bronx, NY
Texas · 1
- The University of Texas MD Anderson Cancer Center · Houston, TX
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.